S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
NASDAQ:SPRB

Spruce Biosciences - SPRB Stock Forecast, Price & News

$3.04
+0.03 (+1.00%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.88
$3.09
50-Day Range
$0.99
$3.09
52-Week Range
$0.95
$3.38
Volume
195,470 shs
Average Volume
3.97 million shs
Market Capitalization
$71.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.80

Spruce Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
196.1% Upside
$9.00 Price Target
Short Interest
Bearish
10.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Spruce Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.03) to ($1.92) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

316th out of 1,030 stocks

Pharmaceutical Preparations Industry

147th out of 502 stocks

SPRB stock logo

About Spruce Biosciences (NASDAQ:SPRB) Stock

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

Receive SPRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SPRB Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Spruce Biosciences Inc
SPRB Spruce Biosciences, Inc.
Where Spruce Biosciences Stands With Analysts
Spruce Biosciences hires new Chief Medical Officer
See More Headlines
Receive SPRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SPRB Company Calendar

Last Earnings
11/10/2022
Today
2/02/2023
Next Earnings (Estimated)
3/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SPRB
Fax
N/A
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+123.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-42,290,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.75 per share

Miscellaneous

Free Float
22,170,000
Market Cap
$71.62 million
Optionable
Not Optionable
Beta
2.25

Key Executives

  • Mr. Michael G. Grey (Age 69)
    Exec. Chairman
    Comp: $65k
  • Mr. Samir M. Gharib CPA (Age 40)
    CPA, M.B.A., Pres & CFO
    Comp: $480k
  • Dr. Javier Szwarcberg M.D. (Age 52)
    M.P.H., CEO & Director
  • Dr. Ralph William Charlton III (Age 52)
    M.D., Chief Medical Officer
  • Dr. Libbie Mansell M.B.A.
    Ph.D., Chief Regulatory & Quality Officer
  • Ms. P. J. Ramtin
    Sr. VP of Bus. Operations













SPRB Stock - Frequently Asked Questions

Should I buy or sell Spruce Biosciences stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spruce Biosciences in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRB shares.
View SPRB analyst ratings
or view top-rated stocks.

What is Spruce Biosciences' stock price forecast for 2023?

6 Wall Street research analysts have issued 1-year price targets for Spruce Biosciences' stock. Their SPRB share price forecasts range from $3.00 to $20.00. On average, they anticipate the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 196.1% from the stock's current price.
View analysts price targets for SPRB
or view top-rated stocks among Wall Street analysts.

How have SPRB shares performed in 2023?

Spruce Biosciences' stock was trading at $1.0974 at the start of the year. Since then, SPRB shares have increased by 177.0% and is now trading at $3.04.
View the best growth stocks for 2023 here
.

Are investors shorting Spruce Biosciences?

Spruce Biosciences saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 1,210,000 shares, an increase of 77.1% from the December 31st total of 683,100 shares. Based on an average trading volume of 1,370,000 shares, the short-interest ratio is currently 0.9 days. Currently, 10.0% of the company's stock are sold short.
View Spruce Biosciences' Short Interest
.

When is Spruce Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our SPRB earnings forecast
.

How were Spruce Biosciences' earnings last quarter?

Spruce Biosciences, Inc. (NASDAQ:SPRB) posted its earnings results on Thursday, November, 10th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.06.

When did Spruce Biosciences IPO?

(SPRB) raised $75 million in an initial public offering on Friday, October 9th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets acted as the underwriters for the IPO.

What is Spruce Biosciences' stock symbol?

Spruce Biosciences trades on the NASDAQ under the ticker symbol "SPRB."

Who are Spruce Biosciences' major shareholders?

Spruce Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Marquette Asset Management LLC (0.29%). Insiders that own company stock include Bali Muralidhar, Camilla V Simpson, Holdings A/S Novo and Venture Fund Iii L Rivervest.
View institutional ownership trends
.

How do I buy shares of Spruce Biosciences?

Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spruce Biosciences' stock price today?

One share of SPRB stock can currently be purchased for approximately $3.04.

How much money does Spruce Biosciences make?

Spruce Biosciences (NASDAQ:SPRB) has a market capitalization of $71.62 million. The company earns $-42,290,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.

How can I contact Spruce Biosciences?

The official website for the company is www.sprucebiosciences.com. The company can be reached via phone at 415-655-4168 or via email at investors@sprucebiosciences.com.

This page (NASDAQ:SPRB) was last updated on 2/3/2023 by MarketBeat.com Staff